1. Home
  2. PCRX vs BFC Comparison

PCRX vs BFC Comparison

Compare PCRX & BFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • BFC
  • Stock Information
  • Founded
  • PCRX 2006
  • BFC 1894
  • Country
  • PCRX United States
  • BFC United States
  • Employees
  • PCRX N/A
  • BFC N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • BFC Major Banks
  • Sector
  • PCRX Health Care
  • BFC Finance
  • Exchange
  • PCRX Nasdaq
  • BFC Nasdaq
  • Market Cap
  • PCRX 1.2B
  • BFC 1.1B
  • IPO Year
  • PCRX 2011
  • BFC N/A
  • Fundamental
  • Price
  • PCRX $22.07
  • BFC $117.16
  • Analyst Decision
  • PCRX Buy
  • BFC Buy
  • Analyst Count
  • PCRX 8
  • BFC 2
  • Target Price
  • PCRX $28.38
  • BFC $137.00
  • AVG Volume (30 Days)
  • PCRX 590.9K
  • BFC 164.8K
  • Earning Date
  • PCRX 08-05-2025
  • BFC 07-18-2025
  • Dividend Yield
  • PCRX N/A
  • BFC 1.54%
  • EPS Growth
  • PCRX N/A
  • BFC N/A
  • EPS
  • PCRX N/A
  • BFC 6.93
  • Revenue
  • PCRX $702,772,000.00
  • BFC $165,998,000.00
  • Revenue This Year
  • PCRX $7.90
  • BFC $11.79
  • Revenue Next Year
  • PCRX $11.02
  • BFC $32.03
  • P/E Ratio
  • PCRX N/A
  • BFC $16.90
  • Revenue Growth
  • PCRX 3.08
  • BFC N/A
  • 52 Week Low
  • PCRX $11.16
  • BFC $82.50
  • 52 Week High
  • PCRX $27.64
  • BFC $132.59
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 44.39
  • BFC 40.65
  • Support Level
  • PCRX $20.85
  • BFC $124.53
  • Resistance Level
  • PCRX $22.32
  • BFC $129.12
  • Average True Range (ATR)
  • PCRX 0.84
  • BFC 4.65
  • MACD
  • PCRX 0.01
  • BFC -1.34
  • Stochastic Oscillator
  • PCRX 44.69
  • BFC 9.92

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About BFC Bank First Corporation

Bank First Corp is a United States-based company engaged in providing financial services provides a full range of consumer and commercial financial institution services to individuals and businesses including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.

Share on Social Networks: